{"entity":{"id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","aka":["PHOENIX"],"tldr":"A phase 2 trial of iparomlimab and tuvonralimab in lung cancer, run by Guangdong Association of Clinical Trials, not yet recruiting.","summary":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC is a phase 2, interventional study registered as NCT07416058 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 61 participants, started 2026-01-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: QL1706 (bispecific antibody targeting PD-1 and CLTA-4). Conditions listed: Lung Adenocarcinoma. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1. Lung eligibility wording from the registry: \"The study will enroll adult patients (aged 18-75 years) with histologically confirmed locally advanced or metastatic NSCLC (AJCC 9th Edition, Stage IIIB-IVB), and harbor confirmed actionable driver mutations for which targeted therapies are available; these mutations are stratified as follows: EGFR \". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07416058","url":"https://clinicaltrials.gov/study/NCT07416058"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-adenocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["iparomlimab-tuvonralimab"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07416058","phase":"2","setting":"A Multicenter Study of Iparomlimab and Tuvonralimab (QL1706) Plus Platinum-Based Doublet Chemotherapy and Bevacizumab in PD-L1 ≥50% Non-Squamous Non-Small Cell Lung Cancer With Actionable Genomic Alterations (AGA) Resistant to Prior Targeted Therapy","sponsor":"Guangdong Association of Clinical Trials","enrolled":61,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07416058/","neighbours":{"cancer":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/"}],"drug":[{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}